Copyright © 2025 Shenyang Dasan Pharmaceutical Technology Co., Ltd.
Posting Date：2021-08-30
Views： 以下是该段内容的英文翻译： ---
On August 26, the strategic cooperation signing ceremony between Beijing New Leading Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as "New Leading Pharmaceutical") and DASAN PHARMACEUTICAL CO., LTD., Korea / Shenyang Dasan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Dasan Pharmaceutical") was held at the New Leading Beijing Research Institute.
Mr. Tao Xinhua, Chairman of New Leading Pharmaceutical; Ms. Gao Shijing, President of New Leading Pharmaceutical; Mr. Zhang Ronghuo, Vice President and General Manager of the Clinical Division; Mr. Yan Yaodong, Vice President; Mr. Kang Jianlei, Vice President and Chief Technology Officer; Mr. Pan Xuan, former researcher at the Chinese Academy of Medical Sciences & Peking Union Medical College and expert advisor to New Leading Pharmaceutical; along with relevant technical staff, as well as Mr. Ryu Hyung-sun, Chairman of Korea Dasan Pharm / Shenyang Dasan Pharmaceutical; Mr. Liu Zhenhao, Vice Chairman of Shenyang Dasan Pharmaceutical; and Mr. Yan Dong, General Manager of Shenyang Dasan Pharmaceutical, attended the signing ceremony.
▲ Ms. Gao Shijing, President of New Leading Pharmaceutical, and Mr. Ryu Hyung-sun, Chairman of Dasan Pharmaceutical, sign on behalf of each party
The Cooperation
DASAN PHARMACEUTICAL CO., LTD., Korea, founded in 1996, is a pharmaceutical formulation R&D, registration, and manufacturing company based on Micro Particle Coating technology. It operates multiple 500kg-grade coating fluidized bed production lines and is a major supplier of Micro Particle Coating intermediates to top 10 pharmaceutical companies in Korea.
Dasan Pharmaceutical provides professional services in advanced and complex formulation technology development, registration, and contract manufacturing to global clients, with business operations spanning Japan, China, Southeast Asia, Europe, North America, and South America. Through its R&D center in Shenyang, it transfers advanced pharmaceutical technologies and products from Korea, Japan, Europe, and the United States to China, offering professional services to Chinese clients and facilitating the entry of final products into the Chinese market.
Dasan Pharmaceutical's business scope also includes the production and sale of finished drug products, active pharmaceutical ingredients (APIs), and natural product extracts. It is the largest supplier of angiotensin II receptor antagonist (ARB) drugs in Korea.
▌Shenyang Dasan Pharmaceutical Technology
Shenyang Dasan Pharmaceutical Technology Co., Ltd. is a high-tech enterprise focused on drug delivery system development, providing pharmaceutical formulation technology development, formulation process optimization, generic drug quality一致性评价, and drug product registration services to the pharmaceutical industry both domestically and internationally.
Shenyang Dasan is a high-end drug formulation R&D center established in China by Korea's DASAN Pharmaceutical. It introduces Korean technology to develop complex and advanced formulations such as enteric-coated pellets, taste-masking granules, sustained-release pellets, gastroretentive tablets, and bilayer tablets, providing industrial-scale technologies for complex high-end formulations tailored to the Chinese market. At the same time, it helps introduce advanced pharmaceutical technologies and products from Korea, Europe, the United States, and Japan into China, serving the Chinese pharmaceutical industry.
▌Beijing New Leading Pharmaceutical Technology
Beijing New Leading Pharmaceutical Technology Development Co., Ltd. is an integrated professional service provider offering pharmaceutical preclinical research, clinical CRO, CDMO services, drug registration, project evaluation, and R&D investment and financing management to pharmaceutical companies worldwide. With a team of over a thousand professionals, it has extensive successful experience in pharmaceutical research, clinical research, drug development, and registration. The company has also established an innovative drug R&D and production service center at the Zhengzhou Airport Economy Zone Biomedical Park, forming a "New Leading CXO" full-industry-chain service system that provides diversified services throughout the entire lifecycle of pharmaceutical R&D.
——————————————————————————————————————————————
▲ Chairman Tao Xinhua delivers a speech
Chairman Tao Xinhua stated that New Leading Pharmaceutical, as one of China's top 10 pharmaceutical R&D companies, has always maintained an open and inclusive attitude with an international perspective. He expressed hope that this cooperation with the Korean company would mark the beginning of a new chapter in New Leading's internationalization efforts, fulfilling the corporate vision of "Enabling China's new drug technology and manufacturing processes to keep pace with the world." The signing ceremony specially invited experts and leaders from industry, academia, and research in the pharmaceutical field to witness and participate. He hoped that all parties would deepen communication, pool their strengths, achieve resource sharing and value complementarity, deepen industry-academia-research cooperation, form pharmaceutical industry clusters, and support the development of the greater health industry.
▲ Chairman Ryu Hyung-sun delivers a speech
Chairman Ryu Hyung-sun stated that after years of relentless effort, Dasan has risen to the forefront of Korean pharmaceutical companies, gradually establishing cooperation with numerous companies in Japan, Central and South America, and other regions across its value chain—from API production and intermediate sales to finished product sales. Chairman Ryu has deep ties with China and believes that the cooperation with New Leading will address Dasan's development shortcomings. He expressed confidence that New Leading would become a solid partner. "Happy people create a healthy world," he said, expressing hope that a happy Dasan and a happy New Leading could work together to create a healthy China, a healthy Korea, and a healthy world.
▲ General Manager Yan Dong presents a special report on "Industrialization Technology Development for Pellet Coating"
▲ Chairman Ryu Hyung-sun visits New Leading's laboratory
Through this strategic cooperation, both parties will strengthen industrial collaboration, promote resource complementarity, and fully leverage New Leading Pharmaceutical's extensive successful experience in drug R&D and registration, as well as Dasan Pharmaceutical's advanced coating technology, sustained-release pellet technology, and abundant external resources, to achieve the R&D and production of innovative drugs and improved new drugs. Together, they aim to build a bridge for Sino-Korean cooperation, jointly establish technology platforms for advanced and complex formulations, and bring outstanding Korean products—such as pediatric and geriatric medications—to China, benefiting more Chinese people.
The event specially invited numerous guests to witness this important moment and engage in thorough exchanges and discussions on the introduction of advanced and complex formulation technologies and the establishment of technology platforms.
Guests participating in this event included (listed alphabetically by institution name):
Mr. Zhao Zongye, Director of R&D Department, Beijing Jingzhi Pharmaceutical
Professor Lu Zhonglin, Party Secretary of the School of Chemistry, Beijing Normal University
Mr. Li Xiaodong, Director of Innovation Center, Shimadzu (China)
Mr. Wang Hongfeng, Chairman, Guizhou Liensheng Pharmaceutical
Mr. Wang Haisheng, Vice President, Harbin Pharmaceutical Group
Mr. Sheng Baodong, General Manager, Hefei Yifan Biopharmaceutical
Ms. Li Shasha, General Manager, China Resources Life Sciences Park Operation Company
Ms. Jiang Haixia, Deputy General Manager, China Resources Life Sciences Park Operation Company
Mr. Xiao Wenhua, Founder, Huaxuejia.com
Ms. Sun Huan, Director of Global Business Development Center, Sihuan Pharmaceutical
Mr. Zhang Ran, Co-founder, Yaofenxiang
Ms. Zhu Rui, Deputy Director of Zhongguancun Lianchuang Medical Engineering Transformation Center, Director of R&D and Transformation Service Committee of China Food and Drug Enterprises Quality and Safety Promotion Association
Ms. Lyu Donghong, Deputy Technical Director, Pharmaceutical Industry Chamber of All-China Federation of Industry and Commerce
…
-END-
Previous：
Back to List